Search hospitals > Washington > Tacoma
MultiCare Institute for Research and Innovation
Claim this profileTacoma, Washington 98405
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Syndrome
Conducts research for Prostate Cancer
112 reported clinical trials
8 medical researchers
Summary
MultiCare Institute for Research and Innovation is a medical facility located in Tacoma, Washington. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Syndrome, Prostate Cancer and other specialties. MultiCare Institute for Research and Innovation is involved with conducting 112 clinical trials across 290 conditions. There are 8 research doctors associated with this hospital, such as Jennifer Slim, John A. Keech, Anuradha Belur, MD, and Bhuvana Sunil.Area of expertise
1Breast Cancer
Global LeaderER positive
HER2 negative
Stage III
2Cancer
Global LeaderStage IV
alkaline phosphatase
Stage II
Top PIs
Jennifer SlimMultiCare Tacoma General Hospital6 years of reported clinical research
Studies Cancer
Studies Breast Cancer
18 reported clinical trials
50 drugs studied
John A. KeechMultiCare Auburn Medical Center9 years of reported clinical research
Studies Breast Cancer
Studies Ovarian Cancer
3 reported clinical trials
12 drugs studied
Anuradha Belur, MDMultiCare Institute for Research and Innovation2 years of reported clinical research
Studies Diarrhea
Studies Solid Tumors
2 reported clinical trials
3 drugs studied
Bhuvana SunilMultiCare Institute for Research & Innovation2 years of reported clinical research
Studies Type 1 Diabetes
Studies Precocious Puberty
2 reported clinical trials
2 drugs studied
Clinical Trials running at MultiCare Institute for Research and Innovation
Non-Hodgkin's Lymphoma
Multiple Sclerosis
Iron-Deficiency Anemia
Spinal Muscular Atrophy
Breast Cancer
Lymphoma
Obesity
Syndrome
Small Cell Lung Cancer
Colorectal Cancer
Epcoritamab + R-CHOP
for Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). The purpose of this study is to assess the change in disease activity of epcoritamab when combined with intravenous and oral rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone (R-CHOP) or R-CHOP in adult participants globally with diffuse large b-cell lymphoma (DLBCL). Change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of DLBCL. Study doctors put the participants in groups called treatment arms. Participants will receive epcoritamab combined with R-CHOP, followed by epcoritamab or R-CHOP followed by rituximab will be explored. Approximately 900 adult participants with with newly diagnosed DLBCL will be enrolled in the study in approximately 315 sites in globally. In the Arm 1, participants will receive subcutaneous epcoritamab combined with intravenous and oral R-CHOP followed by subcutaneous epcoritamab in 21-day cycles. In the Arm 2, participants will receive intravenous and oral R-CHOP followed by intravenous rituximab in 21-day cycles. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Recruiting2 awards Phase 3
Epcoritamab Combo
for Non-Hodgkin's Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cell (a white blood cell responsible for fighting infections). The purpose of this study is to assess the safety and tolerability of epcoritamab in combination with anti-neoplastic agents in adult participants with Non-Hodgkin lymphoma (NHL). Adverse events and change in disease activity will be assessed. Epcoritamab is an investigational drug being developed for the treatment of NHL. Study doctors put the participants in groups called treatment arms. The combination of epcoritamab with anti-neoplastic agents will be explored. Each treatment arm receives a different treatment combination depending on eligibility. Approximately 394 adult participants with NHL will be enrolled in 100 sites globally. In both the dose escalation and dose expansion arms participants will receive subcutaneous (SC) epcoritamab in 28-day or 21 day cycles dependent on the arm in combination with the anti-neoplastic agents described below: 1: Oral lenalidomide in participants with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL); 2: Oral ibrutinib and oral lenalidomide in participants with with R/R DLBCL; 3: Intravenous (IV) polatuzumab vedotin, IV rituximab, IV cyclophosphamide, IV doxorubicin hydrochloride (HCl), and oral prednisone (pola-R-CHP) in participants with newly diagnosed treatment-naïve DLBCL; 4: Oral CC-99282 in participants with R/R DLBCL; 5: Oral CC-99282 in participants with R/R follicular lymphoma (FL); 6A: Oral ibrutinib in participants with R/R mantle cell lymphoma (MCL); 6B: Oral ibrutinib, and oral venetoclax in participants with R/R MCL; 7: Oral ibrutinib, and oral venetoclax in participants with newly diagnosed treatment-naïve MCL. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Recruiting1 award Phase 210 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at MultiCare Institute for Research and Innovation?
MultiCare Institute for Research and Innovation is a medical facility located in Tacoma, Washington. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Syndrome, Prostate Cancer and other specialties. MultiCare Institute for Research and Innovation is involved with conducting 112 clinical trials across 290 conditions. There are 8 research doctors associated with this hospital, such as Jennifer Slim, John A. Keech, Anuradha Belur, MD, and Bhuvana Sunil.